The effect of Erigeron breviscapus capsule on Type 2 diabetic nephropathy of mice induced by high-fat diet combined with streptozocin
The aim of the study is to explore the effect of Erigeron breviscapus capsule on diabetic nephropathy mice.C57BL/6J mice were fed with high-fat diet(HFD)for successive 12 weeks and then intraperitoneally injected with streptozotocin(STZ)to establish the diabetic nephropathymodel.After that,mice were randomly divided into model group,positive control(benazepril,10 mg/kg)and three doses of Erigeron breviscapus capsule(0.75,1.5 and 3 g/kg),eight mice each group.Meantime,another eight non-HFD mice was selected as normal group,only fed with standard diet.After six weeks of continuous administration of the test substances,these parameters including fasting blood glucose(FBG),24 h urinary protein and serum triglyceride(TG),total cholesterol(TC),low density lipoprotein(LDL),albumin(ALB),creatinine(Cre),urea nitrogen(BUN)and fasting insulin(FINS)levels were detected.HE staining was used to determine the pathological changes of kidney.Results showed thatFBG,uri-nary protein,Cre and BUN levels increased significantly as accompanied by the injury of end-stage renal function after the induction of HFD combined with STZ.Simultaneously,glomerular hypertrophy,mesangial expansion and basement membrane thickening were observed through pathological examination.As expected,these indexes were improved on the Erigeron breviscapus capsule treated mice as well as the kidney ratios decreasing.Overall,Erigeron breviscapus capsule has the potential for treating type 2 diabetic nephropathy mainly manifested as protecting renal function to a certain extent,and delaying the decline of renal function.
Erigeron breviscapus capsuletype 2 diabetic nephropathyhight-fat dietstreptozocinurinary protein
万方数据
维普
